|
"chiu cf"的相关文件
显示项目 31-80 / 115 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-10-01 |
Pharmacokinetic study of florfenicol in Bester sturgeon, a cultured hybrid of Huso huso × Acipenser ruthenus by high performance liquid chromatography equipped with UV detector
|
Hung, YW;Lin, YH;Chen, MH;Wang, WS;Chiu, CF;Chiu, CC;Chiu, HW;Tsai, WH;Hung, SW |
| 國家衛生研究院 |
2018-02 |
HIF-1alpha promotes autophagic proteolysis of Dicer and enhances tumor metastasis
|
Lai, HH;Li, JN;Wang, MY;Huang, HY;Croce, CM;Sun, HL;Lyu, YJ;Kang, JW;Chiu, CF;Hung, MC;Suzuki, HI;Chen, PS |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g
|
Macarulla, TM;Hubner, R;Blanc, JF;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Yanshen, S;Jameson, GS;Lee, KH;Chiu, CF;Schwartsmann, G;Braiteh, FS;Cunningham, D;Chen, LT;Von Hoff, DD;Mamlouk, KK;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2018-01 |
Epigenetic regulation of LDHA dictates the gemcitabine resistance in pancreatic cancer
|
Chiu, CF |
| 國家衛生研究院 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Blanc, JF;Hubner, R;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Mercade, TM;Lee, KH;Cunningham, D;Chiu, CF;Schwartsmann, G;Braiteh, F;von Hoff, D;Chen, LT;Mamlouk, K;de Jong, F;Siveke, J |
| 國家衛生研究院 |
2017-11 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Shan, YS;Mercade, TM;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, J;Belanger, B;de Jong, F;Mamlouk, K;von Hoff, D |
| 國家衛生研究院 |
2017-07 |
Terminally Ill Taiwanese cancer patients’ and family caregivers’ agreement on patterns of life-sustaining treatment preferences is poor to fair and declines over a decade: Results from two independent cross-sectional studies
|
Liu, TW;Wen, FH;Wang, CH;Hong, RL;Chow, JM;Chen, JS;Chiu, CF;Tang, ST |
| 國家衛生研究院 |
2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Jean-Frederic, B;Richard, H;Li, CP;Andrea, WG;Gyorgy, B;Andrew, D;Shan, YS;Gayle, J;Teresa, M;Lee, H;David, C;Chiu, CF;Gilberto, S;Fadi, B;Daniel, V;Chen, LT;Khalid, M;Parul, B;Floris, D;Jens, S |
| 國家衛生研究院 |
2017-06-26 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Andrea, WG;Shan, YS;Teresa, M;Jean-Frederic, B;Richard, H;Chiu, CF;Gilberto, S;Jens, S;Marc, PJ;Bruce, B;Floris, D;Khalid, M;Daniel, V |
| 國家衛生研究院 |
2017-02-03 |
E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer [Erratum: Annals of Surgical Oncology. 2015;22(3):889-898.]
|
Chen, HA;Chang, YW;Tseng, CF;Chiu, CF;Hong, CC;Wang, W;Wang, MY;Hsiao, M;Ma, JT;Chen, CH;Jiang, SS;Wu, CH;Hung, MC;Huang, MT;Su, JL |
| 國家衛生研究院 |
2017-02 |
Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO
|
Chen, LT;Wang-Gillam, A;Yanshen, S;Macarulla, T;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Pipas, JM;Belanger, B;de Jong, F;Mamlouk, K;Von Hoff, DD |
| 國家衛生研究院 |
2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
|
Chen, LT;Li, CP;Chiu, CF;Shan, YS;Park, JO;Chen, JS;Kim, JS;Rau, KM;de Jong, F;Pipas, M;Belanger, B;Wang, E;Lee, KH;Bang, YJ |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-07 |
Dicer elicits paclitaxel chemosensitization and suppresses cancer stemness in breast cancer by repressing AXL
|
Chang, TY;Chen, HA;Chiu, CF;Chang, YW;Kuo, TC;Tseng, PC;Wang, W;Hung, MC;Su, JL |
| 國家衛生研究院 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-04-18 |
NF-kappaB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance
|
Chiu, CF;Chang, YW;Kuo, KT;Shen, YS;Liu, CY;Yu, YH;Cheng, CC;Lee, KY;Chen, FC;Hsu, MK;Kuo, TC;Ma, JT;Su, JL |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
| 國家衛生研究院 |
2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, JT;Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Braiteh, F;Moyo, V;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy
|
Chiang, NJ;Yeh, KH;Chiu, CF;Chen, JS;Yen, CC;Lee, KD;Lin, YL;Bai, LY;Chen, MH;Lin, JS;Yang, Y;Rau, KM;Hsiao, HH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2015-07 |
CARMA3 represses metastasis suppressor NME2 to promote lung cancer stemness and metastasis
|
Chang, YW;Chiu, CF;Lee, KY;Hong, CC;Wang, YY;Cheng, CC;Jan, YH;Huang, MS;Hsiao, M;Ma, JT;Su, JL |
| 亞洲大學 |
2015-07 |
CARMA3 Represses Metastasis-Suppressor NME2 to Promote Lung Cancer Stemness and Metastasis
|
Chang, YW;Chang, YW;Chiu, CF;Chiu, CF;Lee, KY;Lee, KY;Hong, CC;Hong, CC;Wang, YY;Wang, YY;Cheng, CC;Cheng, CC;Jan, YH;Jan, YH;Huang, MS;Huang, MS;Hsiao, M;Hsiao, M;蘇振良 |
| 中國醫藥大學 |
2015-07 |
CARMA3 Represses Metastasis-Suppressor NME2 to Promote Lung Cancer Stemness and Metastasis
|
(Chang YW,);(Chiu CF);(Lee KY);(Hong CC);(Wang YY);(Cheng CC);(Jan YH);(Huang MS);(Hsiao M);(Ma JT);蘇振良(Jen-Liang Su)* |
| 國家衛生研究院 |
2015-05 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, JS;Hsu, C;Chiang, NJ;Tsai, CS;Tsou, HH;Huang, SF;Bai, LY;Chang, IC;Shiah, HS;Ho, CL;Yen, CJ;Lee, KD;Chiu, CF;Rau, KM;Yu, MS;Yang, Y;Hsieh, RK;Chang, JY;Shan, YS;Chao, Y;Chen, LT |
| 國家衛生研究院 |
2015-03 |
E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer
|
Chen, HA;Chang, YW;Tseng, CF;Chiu, CF;Hong, CC;Wang, W;Wang, MY;Hsiao, M;Ma, JT;Chen, CH;Jiang, SS;Wu, CH;Hung, MC;Huang, MT;Su, JL |
| 國家衛生研究院 |
2015-02 |
Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma
|
Tsai, HJ;Lin, SF;Chen, CC;Chen, TY;Su, WC;Hwang, WL;Lin, JC;Chiou, TJ;Kao, WY;Chiu, CF;Chang, YF;Chang, JS;Chang, MC;Su, IJ |
| 國家衛生研究院 |
2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E |
| 國立交通大學 |
2014-12-08T15:27:38Z |
CMOS rotation-invariant pattern recognition system
|
Chiu, CF; Wu, CY |
| 國立交通大學 |
2014-12-08T15:03:14Z |
A NEW STRUCTURE OF THE 2-D SILICON RETINA
|
WU, CY; CHIU, CF |
| 國立交通大學 |
2014-12-08T15:01:54Z |
The design of rotation-invariant pattern recognition using the silicon retina
|
Chiu, CF; Wu, CY |
| 國家衛生研究院 |
2014-12 |
Suppression of dicer increases sensitivity to gefitinib in human lung cancer cells
|
Chen, JC;Su, YH;Chiu, CF;Chang, YW;Yu, YH;Tseng, CF;Chen, HA;Su, JL |
| 國家衛生研究院 |
2014-12 |
Physician-patient end-of-life care discussions: Correlates and associations with end-of-life care preferences of cancer patients-a cross-sectional survey study
|
Tang, ST;Liu, TW;Liu, LN;Chiu, CF;Hsieh, RK;Tsai, CM |
| 國家衛生研究院 |
2014-12 |
Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-kappaB signaling in cervical cancer
|
Chang, YW;Chen, MW;Chiu, CF;Hong, CC;Cheng, CC;Hsiao, M;Chen, CA;Wei, LH;Su, JL |
| 國家衛生研究院 |
2014-12 |
Vascular endothelial growth factor-C upregulates cortactin and promotes metastasis of esophageal squamous cell carcinoma
|
Su, CM;Su, YH;Chiu, CF;Chang, YW;Hong, CC;Yu, YH;Ho, YS;Wu, CH;Yen, CS;Su, JL |
| 國家衛生研究院 |
2014-11 |
miR326 maturation is crucial for VEGF-C-driven cortactin expression and esophageal cancer progression
|
Hong, CC;Chen, PS;Chiou, J;Chiu, CF;Yang, CY;Hsiao, M;Chang, YW;Yu, YH;Hung, MC;Hsu, NW;Shiah, SG;Hsu, NY;Su, JL |
| 亞洲大學 |
2014-09 |
E1A-Mediated Inhibition of HSPA5 Suppresses Cell Migration and Invasion in Triple-Negative Breast Cancer
|
Chen, HA;Chen, HA;Chang, YW;Chang, YW;Tseng, CF;Tseng, CF;Chiu, CF;Chiu, CF;Hong, CC;Hong, CC;Wang, W;Wang, W;Wang, MY;Wang, MY;Hsiao, M;Hsiao, M;Ma JT, ;Chen CH, ;Jiang, SS;Jiang, SS;Wu, CH;Wu, CH;洪明奇;Huang, MT;Huang, MT |
| 亞洲大學 |
2014-09 |
miR-326 maturation is crucial for VEGF-C driven cortactin expression and esophageal cancer progression
|
Hong, CC;Hong, CC;Chen, PS;Chen, PS;Chiou, J;Chiou, J;Chiu, CF;Chiu, CF;Yang, CY;Yang, CY;Hsiao, M;Hsiao, M;Chang, YW;Chang, YW;Yu, YH;Yu, YH;Hung MC, ;Hsu NW, ;S;S;Hsu, NY;Hsu, NY;蘇振良* |
| 中國醫藥大學 |
2014-09 |
miR-326 maturation is crucial for VEGF-C driven cortactin expression and esophageal cancer progression
|
(Hong CC);(Chen PS);(Chiou J);(Chiu CF);(Yang CY);(Hsiao M);(Chang YW, , Hung MC);余養豪(Yang-Hao Yu);洪明奇(Mien-Chie Hung);(Hsu NW,);(Shiah SG);(Hsu NY);蘇振良(Jen-Liang Su)* |
| 中國醫藥大學 |
2014-09 |
E1A-Mediated Inhibition of HSPA5 Suppresses Cell Migration and Invasion in Triple-Negative Breast Cancer
|
(Chen HA);(Chang YW);(Tseng CF);(Chiu CF);(Hong CC);(Wang W);(Wang MY);(Hsiao M);(Ma JT);(Chen CH);(Jiang SS, , Hung MC);(Wu CH);洪明奇(Mien-Chie Hung);(Huang MT);蘇振良(Jen-Liang Su)* |
| 中國醫藥大學 |
2014-09 |
Vascular Endothelial Growth Factor-C Upregulates Cortactin and Promotes Metastasis of Esophageal Squamous Cell Carcinoma
|
(Su CM);(Su YH);(Chiu CF);(Chang YW);(Hong CC);余養豪(Yang-Hao Yu);(Ho YS);(Wu CH);(Yen CS);蘇振良(Jen-Liang Su)* |
| 國家衛生研究院 |
2014-07 |
Associations between accurate prognostic understanding and end-of-life care preferences and its correlates among Taiwanese terminally ill cancer patients surveyed in 2011–2012
|
Tang, ST;Liu, TW;Chow, JM;Chiu, CF;Hsieh, RK;Chen, CH;Liu, LN;Feng, WL |
| 國家衛生研究院 |
2014-07 |
Guidelines for treating iron overload in myelodysplastic syndromes: A Taiwan consensus statement
|
Ko, BS;Chang, CS;Chang, MC;Chen, TY;Chiou, TJ;Chiu, CF;Huang, WL;Kao, WY;Lan, YJ;Lin, SF;Tan, TD;Tang, JL;Tzeng, CH;Wang, PN;Yet, SP;Tien, HF |
| 亞洲大學 |
2014-07 |
Arsenic Trioxide Inhibits CXCR4-Mediated Metastasis by Interfering miR-520h/PP2A/NF-κB Signaling in Cervical Cancer
|
Chang, YW;Chang, YW;Chen, MW;Chen, MW;Chiu, CF;Chiu, CF;Hong, CC;Hong, CC;Cheng, CC;Cheng, CC;Hsiao, M;Hsiao, M;Chen, CA;Chen, CA;Wei, LH;Wei, LH;蘇振良* |
| 中國醫藥大學 |
2014-07 |
Arsenic Trioxide Inhibits CXCR4-Mediated Metastasis by Interfering miR-520h/PP2A/NF-κB Signaling in Cervical Cancer
|
(Chang YW);(Chen MW);(Chiu CF);(Hong CC);(Cheng CC);(Hsiao M);(Chen CA);(Wei LH);蘇振良(Jen-Liang Su)* |
| 國家衛生研究院 |
2014-06 |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Hsu, C;Tsou, HH;Lin, SJ;Wang, MC;Yao, M;Hwang, WL;Kao, WY;Chiu, CF;Lin, SF;Lin, J;Chang, CS;Tien, HF;Liu, TW;Chen, PJ;Cheng, AL |
| 中國醫藥大學 |
2014-04 |
Suppression of Dicer Increases Sensitivity to Gefitinib in Human Lung Cancer Cells
|
(Chen JC);(Su YH);(Chiu CF);(Chang YW);余養豪(Yang-Hao Yu);(Tseng CF);(Chen HA);蘇振良(Jen-Liang Su)* |
| 亞洲大學 |
2014-02 |
Hospice shared-care saved medical expenditure and reduced the likelihood of intensive medical utilization among advanced cancer patients in Taiwan-a nationwide survey
|
Lin, WY;Lin, WY;Chiu, TY;Chiu, TY;Ho, CT;Ho, CT;Davidson, LE;Davidson, LE;Hsu, HS;Hsu, HS;Liu, CS;Liu, CS;Chiu, CF;Chiu, CF;彭慶添;Peng, Ching-Tien;Chen CY, ;Hu WY, ;Hsu, LN;Hsu, LN;Li, CI;Li, CI;Li, TC;Li, TC;Lin, CY;Lin, CY |
| 國家衛生研究院 |
2014-01 |
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial
|
Chiang, NJ;Hsu, C;Chen, JS;Tsou, HH;Chao, Y;Shan, YS;Huang, SF;Chiu, CF;Lee, KD;Chen, LT |
显示项目 31-80 / 115 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目
|
